NCT01127269 - Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

178

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

INSULIN GLARGINE

Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)

Trial Locations (23)

2800

Investigational Site Number 25, Zárate

7000

Investigational Site Number 20, Tandil

7600

Investigational Site Number 22, Mar del Plata

C1050AAK

Investigational Site Number 10, C.a.b.a.

C1419AHN

Investigational Site Number 14, C.a.b.a.

Unknown

Investigational Site Number 01, C.a.b.a.

Investigational Site Number 11, C.a.b.a.

Investigational Site Number 12, C.a.b.a.

Investigational Site Number 17, C.a.b.a.

Investigational Site Number 9, C.a.b.a.

Investigational Site Number 03, Caba

Investigational Site Number 06, Caba

Investigational Site Number 15, Caba

Investigational Site Number 16, Caba

Investigational Site Number 18, Caba

Investigational Site Number 26, Capital Federal

Investigational Site Number 02, Mar del Plata

Investigational Site Number 021, Moreno -Pcia. de Bs. As.-

Investigational Site Number 07, Morón

Investigational Site Number 04, Paraná

Investigational Site Number 8, Salta

Investigational Site Number 05, Sarandí

B7602CBM

Investigational Site Number 13, Mar del Plata